Skip to main content
NASDAQ:VYNT

Vyant Bio Competitors

$3.31
+0.43 (+14.93 %)
(As of 05/14/2021 01:27 PM ET)
Add
Compare
Today's Range
$2.87
$3.40
50-Day Range
$2.96
$4.65
52-Week Range
$2.11
$17.50
Volume12,820 shs
Average Volume1.96 million shs
Market Capitalization$36.43 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Vyant Bio (NASDAQ:VYNT) Vs. GANX, EVAX, LGVN, VRDN, UPC, and IKT

Should you be buying VYNT stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Vyant Bio, including Gain Therapeutics (GANX), Evaxion Biotech A/S (EVAX), Longeveron (LGVN), Viridian Therapeutics (VRDN), Universe Pharmaceuticals (UPC), and Inhibikase Therapeutics (IKT).

Vyant Bio (NASDAQ:VYNT) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Valuation and Earnings

This table compares Vyant Bio and Gain Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vyant BioN/AN/AN/AN/AN/A
Gain TherapeuticsN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Vyant Bio and Gain Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vyant Bio0000N/A
Gain Therapeutics00203.00

Gain Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 207.38%. Given Gain Therapeutics' higher probable upside, analysts clearly believe Gain Therapeutics is more favorable than Vyant Bio.

Profitability

This table compares Vyant Bio and Gain Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vyant BioN/AN/AN/A
Gain TherapeuticsN/AN/AN/A

Summary

Gain Therapeutics beats Vyant Bio on 2 of the 2 factors compared between the two stocks.

Vyant Bio (NASDAQ:VYNT) and Evaxion Biotech A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Valuation and Earnings

This table compares Vyant Bio and Evaxion Biotech A/S's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vyant BioN/AN/AN/AN/AN/A
Evaxion Biotech A/SN/AN/AN/AN/AN/A

Profitability

This table compares Vyant Bio and Evaxion Biotech A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vyant BioN/AN/AN/A
Evaxion Biotech A/SN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Vyant Bio and Evaxion Biotech A/S, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vyant Bio0000N/A
Evaxion Biotech A/S00203.00

Evaxion Biotech A/S has a consensus price target of $18.00, suggesting a potential upside of 239.62%. Given Evaxion Biotech A/S's higher probable upside, analysts clearly believe Evaxion Biotech A/S is more favorable than Vyant Bio.

Summary

Evaxion Biotech A/S beats Vyant Bio on 2 of the 2 factors compared between the two stocks.

Longeveron (NASDAQ:LGVN) and Vyant Bio (NASDAQ:VYNT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability.

Valuation & Earnings

This table compares Longeveron and Vyant Bio's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LongeveronN/AN/AN/AN/AN/A
Vyant BioN/AN/AN/AN/AN/A

Profitability

This table compares Longeveron and Vyant Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LongeveronN/AN/AN/A
Vyant BioN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings for Longeveron and Vyant Bio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Longeveron0000N/A
Vyant Bio0000N/A

Viridian Therapeutics (NASDAQ:VRDN) and Vyant Bio (NASDAQ:VYNT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability.

Analyst Recommendations

This is a summary of current ratings for Viridian Therapeutics and Vyant Bio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Viridian Therapeutics00203.00
Vyant Bio0000N/A

Viridian Therapeutics currently has a consensus target price of $34.00, suggesting a potential upside of 94.06%. Given Viridian Therapeutics' higher probable upside, research analysts clearly believe Viridian Therapeutics is more favorable than Vyant Bio.

Valuation & Earnings

This table compares Viridian Therapeutics and Vyant Bio's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viridian TherapeuticsN/AN/AN/AN/AN/A
Vyant BioN/AN/AN/AN/AN/A

Profitability

This table compares Viridian Therapeutics and Vyant Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Viridian TherapeuticsN/AN/AN/A
Vyant BioN/AN/AN/A

Summary

Viridian Therapeutics beats Vyant Bio on 2 of the 2 factors compared between the two stocks.

Vyant Bio (NASDAQ:VYNT) and Universe Pharmaceuticals (NYSE:UPC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, analyst recommendations, profitability and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for Vyant Bio and Universe Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vyant Bio0000N/A
Universe Pharmaceuticals0000N/A

Valuation and Earnings

This table compares Vyant Bio and Universe Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vyant BioN/AN/AN/AN/AN/A
Universe PharmaceuticalsN/AN/AN/AN/AN/A

Profitability

This table compares Vyant Bio and Universe Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vyant BioN/AN/AN/A
Universe PharmaceuticalsN/AN/AN/A

Vyant Bio (NASDAQ:VYNT) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, analyst recommendations, profitability and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for Vyant Bio and Inhibikase Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vyant Bio0000N/A
Inhibikase Therapeutics00103.00

Valuation and Earnings

This table compares Vyant Bio and Inhibikase Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vyant BioN/AN/AN/AN/AN/A
Inhibikase TherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares Vyant Bio and Inhibikase Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vyant BioN/AN/AN/A
Inhibikase TherapeuticsN/AN/AN/A

Summary

Inhibikase Therapeutics beats Vyant Bio on 1 of the 1 factors compared between the two stocks.


Vyant Bio Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
GANX
Gain Therapeutics
1.7$9.76+7.8%$106.89 millionN/A0.00Gap Up
EVAX
Evaxion Biotech A/S
1.7$5.30+5.7%$101.76 millionN/A0.00News Coverage
Gap Up
Trading Halted
LGVN
Longeveron
0.0$5.20+1.9%$98.58 millionN/A0.00News Coverage
VRDN
Viridian Therapeutics
1.7$17.52+3.8%$68.47 millionN/A0.00News Coverage
Gap Up
UPC
Universe Pharmaceuticals
0.0$3.15+1.9%$67.21 millionN/A0.00Gap Up
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
1.0$4.90+9.0%$49.29 millionN/A0.00Gap Down
CUBT
Curative Biotechnology
0.0$0.11+8.7%$44.64 millionN/A0.00Gap Up
Viracta Therapeutics logo
VIRX
Viracta Therapeutics
1.5$7.69+0.4%$39.63 millionN/A0.00Analyst Downgrade
Gap Up
VIRI
Virios Therapeutics
1.3$4.71+2.1%$39.23 millionN/A0.00News Coverage
CMMB
Chemomab Therapeutics
1.7$17.73+6.4%$38.77 millionN/A0.00Earnings Announcement
Analyst Report
News Coverage
Gap Up
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.33+3.9%$37.69 millionN/A0.00Gap Up
MYMD
MyMD Pharmaceuticals
0.0$3.68+1.1%$30.31 millionN/A0.00Upcoming Earnings
VLON
Vallon Pharmaceuticals
0.0$3.71+1.1%$25.27 millionN/A0.00News Coverage
VRPX
Virpax Pharmaceuticals
0.3$3.85+2.6%$19.04 millionN/A0.00Gap Down
BCTX
BriaCell Therapeutics
0.0$3.18+3.1%$17.91 millionN/A0.00Gap Up
PALI
Palisade Bio
0.0$3.88+18.6%$13.26 millionN/A0.00Upcoming Earnings
Gap Down
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.32+0.4%$0.00N/A0.00Earnings Announcement
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.06+0.0%$0.00N/A0.00Gap Down
SCPS
Scopus BioPharma
1.4$5.30+2.5%$0.00N/A0.00
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.